IP Library Granted Patent US 10,278,398
Granted Patent B2
US 10,278,398 · App. 15/481,767 · Granted May 7, 2019

Phage derived antimicrobial activities

Inventors: Sriram Padmanabhan (Bangalore, IN); Vivek Daniel Paul (Bangalore, IN); R. Sanjeev Saravanan (Bangalore, IN); Bharathi Sriram (Bangalore, IN)
Assignee: GangaGen, Inc.
A01N63/02A61K38/50C07K14/00C12N1/20C12N9/2462C12N9/78C07K2319/00C07K2319/035C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,278,398
App. No.
15/481,767
Granted
May 7, 2019
Kind
B2
Abstract

The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.

Claims (9)

1. An expression vector comprising an isolated or recombinant nucleic acid encoding a chimeric polypeptide, wherein the chimeric polypeptide comprises a muralytic domain (MD) having at least 90% sequence identity to the sequence of amino acids 669-808 of SEQ ID NO: 1 and a heterologous cell binding domain (CBD) that binds to a target bacterium, wherein the CBD has a sequence with at least 90% identity to a sequence selected from the group consisting of:

amino acids 144-240 of SEQ ID NO:4,

amino acids 149-257 of SEQ ID NO:8, and

amino acids 144-243 of SEQ ID NO:12,

wherein the target bacterium exhibits reduced or no growth after being contacted with the chimeric polypeptide.

2. The expression vector of claim 1 , wherein the chimeric polypeptide comprises a sequence with at least 90% identity to SEQ ID NO:4.

3. A cell comprising the nucleic acid of claim 1 .

4. The cell of claim 3 , which is a prokaryotic cell.

5. The cell of claim 3 , which secretes the chimeric polypeptide.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2020
From: GANGAGEN, INC.
To: BACTOCLEAR HOLDINGS PTE. LTD.
Reel/Frame 052603/0390 →
RELEASE OF SECURITY INTEREST Recorded Jan 14, 2020
From: ATEL VENTURES, INC.
To: GANGAGEN, INC.
Reel/Frame 051507/0381 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2020
From: GANGAGEN, INC.
To: BACTOCLEAR HOLDINGS PTE. LTD.
Reel/Frame 051499/0244 →
SECURITY INTEREST Recorded Jul 26, 2018
From: GANGAGEN, INC.
To: ATEL VENTURES, INC.
Reel/Frame 046475/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2018
From: PADMANABHAN, SRIRAM; PAUL, VIVEK DANIEL; SARAVANAN, R SANJEEV; SRIRAM, BHARATHI
To: GANGAGEN, INC.
Reel/Frame 045338/0661 →
Continuity (6)
Continuation 14278574 · May 15, 2014
Division 13476750 · May 21, 2012
Division 12299601
Provisional Application 60909340 · Mar 30, 2007
Provisional Application 60797885 · May 5, 2006
Related Publication 20170318817A1 · Nov 9, 2017
Cited By (1)
US 12,263,208